Latest Administration News

Energy World Corporation has reported a US$448.2 million FY2026 loss after impairing its Pagbilao power plant and Australian assets, while the group’s survival remains tied to completing a staged US$350 million turbine sale. The audited report also recasts the Pagbilao LNG Hub as the centrepiece of the company’s next phase, but flags material uncertainty around going concern.

Vection Technologies delivered its first positive full-year operating cash flow and a sharp rise in adjusted EBITDA in FY26. Yet the audited report warns that continued operations depend on stronger sales, margin gains, cost reductions and potential access to further capital.

Jupiter Energy remained operationally cashflow positive in FY2026, but its cash position weakened sharply as revenue declined and drilling plans remained dependent on new funding. The Kazakhstan oil producer also carried US$13.87 million of interest-free promissory note debt after a post-year-end repayment.

Hawthorn Resources reported a wider Australian-dollar loss for FY2026, with revenue falling sharply and cash declining by $1.53 million. The company is directing its remaining balance sheet toward exploration at the Trouser Legs gold joint venture and Mount Bevan’s other minerals project.

Iperion reported a lower loss for the year ended 31 March 2026, but its cash reserves and net assets fell sharply, leaving the NZX-listed materials company reliant on related-party funding and director support. Its Pathoglaze manufacturing operation is also being moved from Malaysia to Singapore while customer trials continue.

KGL Resources says its Jervois copper project is funded through construction and ramp-up after a US$300 million Wheaton agreement and a post-year-end A$300 million equity raising. The company is now targeting a final investment decision in the second half of 2026 and first copper concentrate in 2028, while its annual report highlights the execution risks still attached to that timetable.

Imagion Biosystems has secured central ethics approval for its US Phase 1b/2 trial of the MagSense HER2 imaging agent, removing a key requirement before recruitment can begin. Site activation is now underway, but no patient has yet been enrolled and the announcement provides no clinical data.

Mayne Pharma has settled patent litigation with Sun Pharma over IMVEXXY, establishing 21 October 2032 as the agreed potential generic entry date, subject to court approval. The settlement involves no upfront payment, while one further Paragraph IV dispute remains unresolved.

Paradigm Biopharmaceuticals has entered voluntary administration after its pivotal Phase 3 trial produced an interim efficacy result below the threshold required for continuation. The company’s securities will remain suspended while administrators assess its viability, liabilities and possible restructuring options.

Larvotto Resources has extended high-grade antimony-gold-tungsten mineralisation at Clarks Gully about 100 metres beyond its 2025 resource model, with drilling also identifying several hanging-wall lodes. The results could support a larger resource and a potential underground feed source for Hillgrove, but assays, modelling and permitting work remain outstanding.

Vectus Biosystems has secured a pre-IND Type B meeting with the FDA for its lead IPF drug candidate VB0004. The regulator’s written feedback, expected by mid-November, should clarify the next US development steps but does not yet authorise clinical trials.

Alcidion will roll out its Miya Flow software across four Northern Care Alliance hospitals under a new A$7.5 million contract. About A$4.5 million is expected to be recognised as revenue in the current year, including a six-month renewal of the existing ExtraMed system during implementation.